Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT04543305 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT04543305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04543305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 28, 2020
Completion date
March 21, 2022
Enrollment
16 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, multiple myeloma, myelodysplastic syndromes, non hodgkin lymphoma